Toshihiro Tanaka1, Weici Zhang1, Ying Sun2, Zongwen Shuai3, Asiya Seema Chida4, Thomas P Kenny1, Guo-Xiang Yang1, Ignacio Sanz4, Aftab Ansari5, Christopher L Bowlus6, Gregory C Ippolito7, Ross L Coppel8, Kazuichi Okazaki9, Xiao-Song He1, Patrick S C Leung1, M Eric Gershwin1. 1. Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, Davis, CA. 2. Center for the Treatment and Research of Non-Infectious Liver Diseases, Beijing 302 Hospital, Beijing, China. 3. Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. 4. Department of Medicine, Emory University, Atlanta, GA. 5. Department of Pathology, Emory University, Atlanta, GA. 6. Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Davis, CA. 7. Department of Molecular Biosciences, University of Texas at Austin, Austin, TX. 8. Department of Microbiology, Monash University, Clayton, Victoria, Australia. 9. Department of Gastroenterology and Hepatology, Kansai Medical University, Osaka, Japan.
Abstract
A major problem in autoimmunity has been identification of the earliest events that lead to breach of tolerance. Although there have been major advances in dissecting effector pathways and the multilineage immune responses to mitochondrial self-antigens in primary biliary cholangitis, the critical links between environmental factors and tolerance remain elusive. We hypothesized that environmental xenobiotic modification of the E2 subunit of the pyruvate dehydrogenase (PDC-E2) inner lipoyl domain can lead to loss of tolerance to genetically susceptible hosts. Previously we demonstrated that serum anti-PDC-E2 autoantibodies cross-react with the chemical xenobiotics 2-octynoic acid and 6,8-bis (acetylthio) octanoic acid and further that there is a high frequency of PDC-E2-specific peripheral plasmablasts. Herein we generated 104 recombinant monoclonal antibodies (mAbs) based on paired heavy-chain and light-chain variable regions of individual plasmablasts derived from primary biliary cholangitis patients. We identified 32 mAbs reactive with native PDC-E2, including 20 specific for PDC-E2 and 12 cross-reactive with both PDC-E2 and 2-octynoic acid and 6,8-bis (acetylthio) octanoic acid. A lower frequency of replacement somatic hypermutations, indicating a lower level of affinity maturation, was observed in the complementarity-determining regions of the cross-reactive mAbs in comparison to mAbs exclusively recognizing PDC-E2 or those for irrelevant antigens. In particular, when the highly mutated heavy-chain gene of a cross-reactive mAb was reverted to the germline sequence, the PDC-E2 reactivity was reduced dramatically, whereas the xenobiotic reactivity was retained. Importantly, cross-reactive mAbs also recognized lipoic acid, a mitochondrial fatty acid that is covalently bound to PDC-E2. CONCLUSION: Our data reflect that chemically modified lipoic acid or lipoic acid itself, through molecular mimicry, is the initial target that leads to the development of primary biliary cholangitis. (Hepatology 2017;66:885-895).
A major problem in autoimmunity has been identification of the earliest events that lead to breach of tolerance. Although there have been major advances in dissecting effector pathways and the multilineage immune responses to mitochondrial self-antigens in primary biliary cholangitis, the critical links between environmental factors and tolerance remain elusive. We hypothesized that environmental xenobiotic modification of the E2 subunit of the pyruvate dehydrogenase (PDC-E2) inner lipoyl domain can lead to loss of tolerance to genetically susceptible hosts. Previously we demonstrated that serum anti-PDC-E2 autoantibodies cross-react with the chemical xenobiotics 2-octynoic acid and 6,8-bis (acetylthio) octanoic acid and further that there is a high frequency of PDC-E2-specific peripheral plasmablasts. Herein we generated 104 recombinant monoclonal antibodies (mAbs) based on paired heavy-chain and light-chain variable regions of individual plasmablasts derived from primary biliary cholangitispatients. We identified 32 mAbs reactive with native PDC-E2, including 20 specific for PDC-E2 and 12 cross-reactive with both PDC-E2 and 2-octynoic acid and 6,8-bis (acetylthio) octanoic acid. A lower frequency of replacement somatic hypermutations, indicating a lower level of affinity maturation, was observed in the complementarity-determining regions of the cross-reactive mAbs in comparison to mAbs exclusively recognizing PDC-E2 or those for irrelevant antigens. In particular, when the highly mutated heavy-chain gene of a cross-reactive mAb was reverted to the germline sequence, the PDC-E2 reactivity was reduced dramatically, whereas the xenobiotic reactivity was retained. Importantly, cross-reactive mAbs also recognized lipoic acid, a mitochondrial fatty acid that is covalently bound to PDC-E2. CONCLUSION: Our data reflect that chemically modified lipoic acid or lipoic acid itself, through molecular mimicry, is the initial target that leads to the development of primary biliary cholangitis. (Hepatology 2017;66:885-895).
Authors: Andreas Radbruch; Gwendolin Muehlinghaus; Elke O Luger; Ayako Inamine; Kenneth G C Smith; Thomas Dörner; Falk Hiepe Journal: Nat Rev Immunol Date: 2006-09-15 Impact factor: 53.106
Authors: Phornnop Naiyanetr; Jeffrey D Butler; Liping Meng; Janice Pfeiff; Thomas P Kenny; Kathryn G Guggenheim; Roman Reiger; Kit Lam; Mark J Kurth; Aftab A Ansari; Ross L Coppel; Marcos López-Hoyos; M Eric Gershwin; Patrick S C Leung Journal: J Autoimmun Date: 2011-07-18 Impact factor: 7.094
Authors: Brian K Chung; Bardia T Guevel; Gary M Reynolds; D B R K Gupta Udatha; Eva Kristine Klemsdal Henriksen; Zania Stamataki; Gideon M Hirschfield; Tom Hemming Karlsen; Evaggelia Liaskou Journal: J Autoimmun Date: 2016-10-24 Impact factor: 7.094
Authors: P S Leung; D T Chuang; R M Wynn; S Cha; D J Danner; A Ansari; R L Coppel; M E Gershwin Journal: Hepatology Date: 1995-08 Impact factor: 17.425
Authors: Evaggelia Liaskou; Eva Kristine Klemsdal Henriksen; Kristian Holm; Fatemeh Kaveh; David Hamm; Janine Fear; Marte K Viken; Johannes Roksund Hov; Espen Melum; Harlan Robins; Johanna Olweus; Tom H Karlsen; Gideon M Hirschfield Journal: Hepatology Date: 2015-09-30 Impact factor: 17.425
Authors: Helder I Nakaya; Jens Wrammert; Eva K Lee; Luigi Racioppi; Stephanie Marie-Kunze; W Nicholas Haining; Anthony R Means; Sudhir P Kasturi; Nooruddin Khan; Gui-Mei Li; Megan McCausland; Vibhu Kanchan; Kenneth E Kokko; Shuzhao Li; Rivka Elbein; Aneesh K Mehta; Alan Aderem; Kanta Subbarao; Rafi Ahmed; Bali Pulendran Journal: Nat Immunol Date: 2011-07-10 Impact factor: 25.606
Authors: Caitlin Bohannon; Ryan Powers; Lakshmipriyadarshini Satyabhama; Ang Cui; Christopher Tipton; Miri Michaeli; Ioanna Skountzou; Robert S Mittler; Steven H Kleinstein; Ramit Mehr; Frances Eun-Yun Lee; Ignacio Sanz; Joshy Jacob Journal: Nat Commun Date: 2016-06-07 Impact factor: 14.919
Authors: Isabell Nilsson; Jeremy Palmer; Eirini Apostolou; Carl-Gerhard Gottfries; Muhammad Rizwan; Charlotte Dahle; Anders Rosén Journal: Front Med (Lausanne) Date: 2020-03-31